

CMS granted TriNav a unique procedural code reimbursed at Endovascular Level 4: APC 5194

TriSalus was pleased to announce at the beginning of this year that, after reviewing our clinical and real-world evidence, CMS established the unique HCPCS code C9797 for procedures that use the TriNav Infusion System.¹ HCPCS code C9797 is reimbursed at a Medicare national average rate of \$16,725.¹

To submit a claim for procedures using TriNav:

- Dictate that TriNav was used and cite clinical benefit and expected outcome
- Use Code C9797 for facility reimbursement when TriNav procedures are performed in the hospital outpatient (HOPD) or ambulatory surgery center (ASC) settings
- For Medicare utilization tracking, when reporting HCPCS code C9797, HOPDs should also report HCPCS code C1982 (Catheter, pressure-generating, one-way valve, intermittently occlusive).
 - CMS Transmittal 12552, March 21, 2024: *"Note that HCPCS Code C9797 describes the procedure, while HCPCS Code C1982 describes the device that is used in the procedure."*
- When coding for physician reimbursement do not use C9797, but instead, bill the appropriate embolization or occlusion code for the procedure performed (CPT codes 37241 – 37244).
- More information can be found [here](#)

CMS' action is in line with Real World Evidence indicating that sicker, complex patients, (e.g., those exhibiting larger tumors, multi-focal disease, or who have already received one or more courses of systemic therapy), treated with TriNav have post-procedure results similar to patients with a lower disease burden treated with traditional microcatheters.² CMS' action also comports with clinical data demonstrating that TriNav improves the T:N ratio,³ an important goal in treating complex patients.

If you have any additional questions or would like to speak to a reimbursement specialist, please reach out to us at reimbursement@trisaluslifesci.com.

Indications For Use

The TriNav Infusion System is intended for use in angiographic procedures. It delivers radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.⁴

Contraindications

TriNav is not intended for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).

Rx Only. For the safe and proper use of the TriNav Infusion System, refer to the Instructions for Use.

References

1. The Centers for Medicare & Medicaid Services. New Technology APC Decision Tracker. December 13, 2023. <https://www.cms.gov/files/document/newtechnology-apc-application-decision-tracker.pdf>. Accessed December 18, 2023
2. Keziah Cook, Deepshakhar Gupta, Yunjuan Liu, Chris Miller-Rosales, Fangzhou Wei, Edward Tuttle, Steven C. Katz, Richard Marshak & Alexander Y. Kim (2024) Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases, *Current Medical Research and Opinion*, 40:4, 591-598, DOI: 10.1080/03007995.2024.2322057
3. d'Abadie P, Walrand S, Goffette P, et al. Antireflux catheter improves tumor targeting in liver radioembolization with resin microspheres. *Diagn Interv Radiol* 2021; 27:768–773.
4. TriSalus™ TriNav® Infusion System, Instructions for Use